Introduction: One of the drugs that are added to common treatments in drug-resistant epilepsy is levetiracetam. Objectives: In this study, the effect of levetiracetam and carbamazepine with levetiracetam and sodium valproate on seizure frequency in patients with epilepsy was compared.
Patients and Methods: This study was a clinical trial in which pre-treatment and post-treatment seizures were compared. In this study, 180 patients with generalized seizures (primary or secondary) who were treated with carbamazepine or sodium valproate were included. The patients were divided into two groups based on receiving the drug carbamazepine (group A) and sodium valproate (group B), and they were examined in periods of 4, 8, 12 and 24 weeks after treatment.
Results: The results of the study showed that in the group treated with carbamazepine and levothyrostam, 40% of patients reported drowsiness, but in the group treated with sodium valproate and levetiracetam this rate was lower and 28% of patients reported that patients better tolerate sodium valproate and levetiracetam. Regarding the frequency of seizure, the treated group with carbamazepine and levothyrostam had better results than the treated group with sodium valproate and levetiracetam, although this difference was not significant (P>0.05).
Conclusion: The addition of levetiracetam to the treatment of patients with carbamazepine and sodium valproate had good results and was well tolerated by patients and did not cause any serious side effects in any treatment group.
Levetiracetam, Carbamazepine, Sodium valproate, Epilepsy, Seizure.